A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma
Alpha-9 Oncology USA Inc.
Alpha-9 Oncology USA Inc.
Ankyra Therapeutics, Inc
MonTa Biosciences ApS
ViroMissile, Inc.
Pfizer
Pfizer
Pfizer
Tizona Therapeutics, Inc
Aulos Bioscience, Inc.
Replimune Inc.
Werewolf Therapeutics, Inc.
MacroGenics
ModernaTX, Inc.
Adaptimmune
Second Life Therapeutics
Onchilles Pharma Inc
Ocellaris Pharma, Inc.
Pierre Fabre Medicament
OncoNano Medicine, Inc.
Regeneron Pharmaceuticals
Novelwise Pharmaceutical Corporation
AccSalus Biosciences, Inc.
Transgene
BioInvent International AB
Revolution Medicines, Inc.
Modulation Therapeutics, Inc.
Tempus AI
Vedanta Biosciences, Inc.
Eisai Inc.
Incyte Corporation
TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc.
7 Hills Pharma, LLC
Immuneering Corporation
Memgen, Inc.
Pfizer
Anaveon AG
Incyte Corporation
Incyte Corporation
Leap Therapeutics, Inc.
BioAtla, Inc.
Biogen
Biogen
ImmunoGenesis
Scholar Rock, Inc.
Bristol-Myers Squibb
Incyte Corporation
Cytoastra
Actelion
Altor BioScience